Loading clinical trials...
Loading clinical trials...
Find 701 clinical trials for lymphoma near Philadelphia, Pennsylvania. Connect with research centers in your area.
Showing 321-340 of 701 trials
NCT04609579
This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab (KEYTRUDA®) in participants with advanced solid tumors and lymphoma. The main goals of this study are to: * Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab (KEYTRUDA®). * Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®) * Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®) * Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®)
NCT03323151
Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib. Ibrutinib has been approved by the Food and Drug Administration (FDA) as treatment for patients with mantle cell lymphoma who have received at least one prior therapy. Ixazomib is in a class of medications called proteasome inhibitors. Cancer cells depend on proteasome to provide this protein metabolism (turnover) function to regulate their growth and survival. Ixazomib disrupts a cancer cells' ability to survive by blocking the proteasome and disrupting protein metabolism. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory MCL and to examine the side effects associated with ixazomib in combination with ibrutinib.